Alzheimers research has entered what leading geneticist Rudolph Tanzi, professor at Harvard Medical School, describes as the most exciting single year in two decades. A convergence of findings from multiple research teams has resolved longstanding debates about the disease mechanism, clarified why previous drug trials failed, and opened a realistic path toward both prevention and treatment. For the first time, the field has a coherent, evidence backed model of how Alzheimers disease unfolds, and that model is now guiding a new generation of clinical trials.
What Alzheimers Research Now Tells Us About Amyloid Accumulation
For decades, the central controversy in Alzheimers research was whether amyloid plaques or tau tangles were the primary driver of the disease. Tanzi, who discovered the first Alzheimers gene as a Harvard doctoral student in 1986, has long maintained that amyloid comes first, a position supported by genetics but complicated by the fact that mouse models with amyloid did not develop tau tangles, and clinical trials targeting amyloid repeatedly failed.
The explanation for those failures came from an Australian study that tracked amyloid accumulation in living patients. The data showed that amyloid begins accumulating in the brain approximately 15 years before any symptoms appear. The clinical trials that failed were treating patients who already had full blown Alzheimers disease, long after amyloid had done its damage. As Tanzi put it, treating Alzheimers patients with an amyloid clearing drug at that stage is like giving a cholesterol lowering drug to a patient already in the middle of a heart attack. The hypothesis was not wrong; the timing was.
The Alzheimers in a Dish Breakthrough
The second critical advance came from Tanzis own laboratory. In a study published in 2014, his team modeled Alzheimers disease for the first time in a three dimensional human cell system, using stem cell derived human neurons grown in a gel matrix that mimics the environment of the brain. In this model, amyloid accumulation did lead to tau tangle formation, something that had never been reproducibly demonstrated before and that mouse models had consistently failed to show.
This single finding resolved a 30 year argument in Alzheimers research. Amyloid causes tangles. If amyloid is stopped early enough, tangles do not form. The model also provided a practical platform for testing drug candidates under conditions that more closely replicate the human brain than any prior system.
Early Intervention as the New Direction in Alzheimers Research
Concurrent with the dish model findings, Biogen published results showing that treating patients with mild Alzheimers with an antibody called BIIB037 removed amyloid and produced measurable cognitive improvement. This was the first proof of concept that amyloid targeting, when applied early enough in disease progression, can actually benefit patients rather than simply clearing plaque without functional benefit.
Reisa Sperling at Harvard is now conducting trials treating patients who do not yet have symptomatic disease but whose brain imaging shows elevated amyloid, placing them at high risk. This prevention focused approach, catching the disease before it has caused irreversible damage, represents the most promising near term strategy to emerge from Alzheimers research in decades.
Tanzi himself has two drugs in clinical trials: PBT2, developed through Prana Biotechnology, which prevents amyloid from aggregating so it can be cleared from the brain, and a gamma secretase modulator that reduces amyloid production at the source. As he described it, one stops the spigot, the other unclogs the drain.
Neuroinflammation as the Third Target in Alzheimers Research
The most recent dimension of Alzheimers research to come into focus is neuroinflammation. Autopsy studies of individuals who died cognitively intact despite having brains full of plaques and tangles revealed a key difference: they did not have significant brain inflammation. Whole genome sequencing of those brains identified variants in genes controlling inflammation as the likely protective factor.
The primary genetic regulators of neuroinflammation in Alzheimers appear to be two genes, CD33 and TREM2, which control the activity of microglial cells, the brain’s immune cells. When confronted with dying neurons, microglia respond as if facing a bacterial or viral infection, releasing free radicals that kill nerve cells in a process Tanzi describes as friendly fire. Suppressing this inflammatory cascade without eliminating the protective functions of microglia is now a central objective of Alzheimers research drug development.
Drug screening programs targeting CD33 and TREM2 are now underway, and Tanzi estimates that neuroinflammation targeted therapies could reach patients within 10 to 15 years, possibly faster given how precisely the genetic targets have now been identified.
A Drug Cocktail Approach to Preventing Alzheimers Disease
The emerging framework from Alzheimers research points toward a combination therapy approach: a drug or antibody to prevent amyloid accumulation, a compound to stop tau tangles from spreading once formed, and an inflammation suppressing agent to protect neurons from the microglial immune response. Tanzi envisions a future in which individuals in their 40s receive routine brain imaging, and those with elevated amyloid begin preventive drug therapy, much as patients with high cholesterol begin statins today.
The timeline he projects for amyloid based prevention is five to ten years. For tangles, an antibody from C2N licensed to AbbVie that prevents tau from spreading between neurons is entering clinical trials. For inflammation, the precision of the genetic targets makes a faster development path plausible.
To read more about neurology and neurodegenerative disease research, visit the FOMAT blog. FOMAT conducts Alzheimers and CNS clinical trials at sites across the United States. To learn more about active studies, visit FOMAT’s patient studies page.
For the full source, see the original Harvard Gazette interview at DDDmag.com.